{"id":"W4391430175","doi":"10.1172/jci176454","title":"HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; Knight Cancer Institute, Oregon Health and Science University; G1 Therapeutics; MacroGenics; Puma Biotechnology; Incyte; National Cancer Institute; Natera; Genomic Health; Daiichi Sankyo Europe; Sanofi; Oregon Health and Science University; Gilead Sciences; University of Texas Southwestern Medical Center; Amgen; Pfizer; Susan G. Komen for the Cure; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Trastuzumab; Medicine; Pertuzumab; Lapatinib; Oncology; Internal medicine; KRAS; Neoadjuvant therapy; ErbB; Cancer research; Cancer; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01573704,0.0001673654,0.000771936,0.0002201852,0.00004079983,0.0000890507,0.0001424748,0.0003308935,0.00004848367],"category_scores_gemma":[0.006524024,0.0001000137,0.0003106065,0.0005276456,0.0004571195,0.0001688051,0.00003224652,0.001352117,0.000006917021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005171587,"about_ca_system_score_gemma":0.002539968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000347133,"about_ca_topic_score_gemma":0.001035178,"domain_scores_codex":[0.9923057,0.004111971,0.002311567,0.0003221314,0.0006865177,0.0002621066],"domain_scores_gemma":[0.9941798,0.004580426,0.0004475474,0.0001939167,0.0002410965,0.0003571411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07342274,0.001336703,0.8455132,0.0000662067,0.0003568424,0.0008786658,0.001178503,0.0000190862,0.0003113018,0.00004860837,0.002214595,0.07465357],"study_design_scores_gemma":[0.02157461,0.005534036,0.9680168,0.001486914,0.000139021,0.0001273218,0.0001683103,0.0008537507,0.000202686,0.0003855653,0.001415562,0.00009542706],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9578397,0.0009855087,0.000003532874,0.03925195,0.000952972,0.0008623131,0.0000448422,0.0000115516,0.00004763028],"genre_scores_gemma":[0.9943945,0.002304156,0.0001361169,0.001090894,0.001901966,0.00005227523,0.000007296697,0.00002180128,0.00009093874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1225036,"threshold_uncertainty_score":0.7810337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2593482090986527,"score_gpt":0.5403783004386817,"score_spread":0.281030091340029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}